GlassScriptPhysician profile
James S Pratty
NPI 1528049608
$598,451.62
in general payments reported to CMS, 2019-2025
23 companies · $78K in 2025
The $78K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $54K · 2021: $94K · 2022: $69K · 2023: $101K · 2024: $61K · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $192K · Travel and Lodging: $29K · Food and Beverage: $9,718 · Consulting Fee: $8,811 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $192,415.00 |
| Travel and Lodging | $29,136.57 |
| Food and Beverage | $9,717.57 |
| Consulting Fee | $8,811.25 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $145,861.70 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107,779.53 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $98,757.43 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Allergan, INC. | $61,224.08 | 2019-2021 | |
| Alkermes, INC. | $54,487.83 | 2019-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $51,198.59 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $36,473.76 | 2019-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $29,884.57 | 2019-2024 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $9,100.02 | 2019-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $1,483.33 | 2019-2025 | Invega Trinza, Invega Sustenna |
| Idorsia Pharmaceuticals US INC | $1,190.00 | 2023 | Quviviq |
| Bausch Health US, LLC | $305.79 | 2019-2025 | Aplenzin |
| Luye Pharma (USA) LTD. | $227.46 | 2025 | Erzofri Extended-Release |
| E.R. Squibb & Sons, L.L.C. | $119.17 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $87.25 | 2019-2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $59.89 | 2024-2025 | Rexulti |
| Eisai INC. | $49.32 | 2021 | |
| Axsome Therapeutics, INC. | $41.97 | 2023-2025 | Auvelity |
| Indivior INC. | $27.57 | 2020 | |
| Acadia Pharmaceuticals INC | $24.77 | 2019 | |
| Avanir Pharmaceuticals, INC. | $24.04 | 2019 | |
| Ge Healthcare | $23.62 | 2020 | |
| Shire North American Group INC | $19.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pratty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.